Daniella Beckman, CFO of Tango Therapeutics ($TNGX), sold shares on the open market twice in the last year, totaling about $127,000. Her most recent sale occurred on February 3, 2026. These TNGX insider sales rank 9,230th among nearly 12,000 individual insiders, far below the average of $8.6 million per seller and 6.4 transactions. Beckman made no open market purchases in the period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 2, 2026 | Tango Therapeutics, Inc. | $TNGX | Beckman Daniella | Chief Financial Officer | A | Common Stock | 44330 | $0.00 | 194,614.0000 | 134,593,998 | 29.50% | 0.03% |
| Feb. 2, 2026 | Tango Therapeutics, Inc. | $TNGX | Beckman Daniella | Chief Financial Officer | A | Stock Option (Right to Buy) | 265980 | $0.00 | 265,980.0000 | 134,593,998 | 9999.99% | 0.20% |
| Feb. 3, 2026 | Tango Therapeutics, Inc. | $TNGX | Beckman Daniella | Chief Financial Officer | S | Common Stock | 113 | $12.90 | 184,297.0000 | 134,593,998 | 0.06% | 0.00% |
| Feb. 3, 2026 | Tango Therapeutics, Inc. | $TNGX | Beckman Daniella | Chief Financial Officer | S | Common Stock | 10204 | $12.26 | 184,410.0000 | 134,593,998 | 5.24% | 0.01% |
| June 10, 2025 | Upstream Bio, Inc. | $UPB | Beckman Daniella | Not found | A | Stock Option (Right to Buy) | 17096 | $0.00 | 17,096.0000 | 53,640,895 | 9999.99% | 0.03% |
| May 22, 2025 | Vor Biopharma Inc. | $VOR | Beckman Daniella | Not found | A | Stock Option (Right to Buy) | 30000 | $0.00 | 30,000.0000 | 124,851,547 | 9999.99% | 0.02% |
| Feb. 4, 2025 | Tango Therapeutics, Inc. | $TNGX | Beckman Daniella | Chief Financial Officer | S | Common Stock | 4284 | $2.99 | 154,232.0000 | 0 | 2.70% | 0.00% |
| Feb. 5, 2025 | Tango Therapeutics, Inc. | $TNGX | Beckman Daniella | Chief Financial Officer | S | Common Stock | 3948 | $3.16 | 150,284.0000 | 0 | 2.56% | 0.00% |
| Feb. 3, 2025 | Tango Therapeutics, Inc. | $TNGX | Beckman Daniella | Chief Financial Officer | A | Common Stock | 26119 | $0.00 | 158,516.0000 | 0 | 19.73% | 0.00% |
| Feb. 3, 2025 | Tango Therapeutics, Inc. | $TNGX | Beckman Daniella | Chief Financial Officer | A | Stock Option (Right to Buy) | 156713 | $0.00 | 156,713.0000 | 0 | 9999.99% | 0.00% |
| Oct. 10, 2024 | Upstream Bio, Inc. | $UPB | Beckman Daniella | Not found | A | Stock Option (Right to Buy) | 34681 | $0.00 | 34,681.0000 | 0 | 9999.99% | 0.00% |
| May 23, 2024 | Vor Biopharma Inc. | $VOR | Beckman Daniella | Not found | A | Stock Option (Right to Buy) | 30000 | $0.00 | 30,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 7, 2024 | Tango Therapeutics, Inc. | $TNGX | Beckman Daniella | Chief Financial Officer | S | Common Stock | 1817 | $12.62 | 132,397.0000 | 0 | 1.35% | 0.00% |
| Feb. 6, 2024 | Tango Therapeutics, Inc. | $TNGX | Beckman Daniella | Chief Financial Officer | S | Common Stock | 1908 | $12.56 | 134,214.0000 | 0 | 1.40% | 0.00% |
| Feb. 1, 2024 | Tango Therapeutics, Inc. | $TNGX | Beckman Daniella | Chief Financial Officer | A | Stock Option (Right to Buy) | 236475 | $0.00 | 236,475.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2024 | Tango Therapeutics, Inc. | $TNGX | Beckman Daniella | Chief Financial Officer | A | Common Stock | 39413 | $0.00 | 39,413.0000 | 0 | 9999.99% | 0.00% |
| May 26, 2023 | Vor Biopharma Inc. | $VOR | Beckman Daniella | Director | A | Stock Option (right to buy) | 30000 | $0.00 | 30,000.0000 | 0 | 9999.99% | 0.00% |